<DOC>
	<DOCNO>NCT00082979</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , breast duct endoscopy , may improve ability detect breast cancer earlier plan effective treatment . PURPOSE : This phase II trial study well breast duct endoscopy work assess cellular atypia ( abnormal cell ) breast duct woman genetic risk breast cancer .</brief_summary>
	<brief_title>Duct Endoscopy Assessing Cellular Atypia Breast Duct Fluid Women With Genetic Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Correlate cell yield morphology finding ductal lavage duct endoscopy finding subsequent surgical pathology finding high-risk woman BRCA1 , BRCA2 , p53 gene mutation cellular atypia . - Determine prevalence occult breast cancer patient cellular atypia undergoing duct endoscopy . Secondary - Determine patient acceptance duct endoscopy . - Perform immunohistochemical analysis ( include estrogen receptor , progesterone receptor , HER2-neu receptor , epidermal growth factor receptor , p53 , proliferation marker expression ) marker potentially associate breast cancer patient . - Determine potential molecular marker malignancy gene methylation , gene expression , proteomics patient . OUTLINE : Patients undergo nipple aspiration identify productive duct collect fluid tumor marker assessment follow ductal lavage 15 minute . Patients undergo duct endoscopy approximately 30 minute local anesthesia . If abnormality find , duct endoscopy repeat 6 month . If repeat duct endoscopy normal , patient continue undergo nipple aspiration ductal lavage specify protocols RMNHS-2242 RMNHS-2269 . If abnormality find either initial repeat duct endoscopy , patient may undergo assessment comprise image biopsy and/or appropriate surgical intervention . Fluid analyze tumor marker immunohistochemistry . Candidate gene analyze gene methylation study , gene expression array , proteomic analysis . Patients follow least 5 year . PROJECTED ACCRUAL : A total 45-60 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cellular atypia nipple aspirate ductal lavage fluid Enrollment RMNHS2242 RMNHS2269 require No inflammatory breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 64 Sex Female Menopausal Status Any status Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No prior allergy eutectic mixture local anesthetic ( EMLAÂ® ) cream lidocaine No severe illness would preclude study participation No mental illness handicap would preclude study compliance No active infection inflammation breast study No nursing within past 12 month Not pregnant Not unconscious PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No prior tamoxifen Radiotherapy Not specify Surgery No prior subareolar surgery ( e.g. , papilloma resection , biopsy , fine needle aspiration ) surgery may disrupt ductal system within 2 cm nipple Biopsies fine needle aspiration &gt; 2 cm nipple allow No prior breast implantation propose lavage side Other No prior chemopreventative agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>breast cancer</keyword>
</DOC>